# US 2013/0158006 A1 · Aminopyrimidine derivatives as lrrk2 modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158006 A1
- Document ID: US20130158006A1
- Status: Published application
- Kind: A1
- Application number: 13/687,429
- Filed: 2012-11-28
- Published: 2013-06-20
- Earliest claimed: 2011-11-29
- Assignees: Genentech, Inc.
- Inventors: Charles Baker-Glenn; Mark Chambers; Bryan K. Chan; Anthony Estrada; Zachary Kevin Sweeney
- Web page: https://patentgrep.com/patent/US20130158006A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/04: Antibacterial agents
- A61P 31/08: for leprosy
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 498/08: Bridged systems
- C07D 239/47: One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C07D 239/48: Two nitrogen atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

## Claims

### Claim 1

A compound of formula I:
or pharmaceutically acceptable salts thereof,
wherein:
A is a five- or six-membered saturated or unsaturated ring that includes one or two heteroatoms selected from O, N and S, which is substituted once with R5, and which is optionally substituted one, two or three times with R6;
X is: —NRa—; —O—; or —S(O)r— wherein r is from 0 to 2 and Ra is hydrogen or C1-6alkyl;
R1 is: C1-6alkyl; C1-6alkenyl; C1-6alkynyl; halo-C1-6alkyl; C1-6alkoxy-C1-6alkyl; hydroxy-C1-6alkyl; amino-C1-6alkyl; C1-6alkylsulfonyl-C1-6alkyl; C3-6cycloalkyl optionally substituted with C1-6alkyl; C3-6cycloalkyl-C1-6alkyl wherein the C3-6cycloalkyl portion is optionally substituted with C1-6alkyl; tetrahydrofuranyl; tetrahydrofuranyl-C1-6alkyl; oxetanyl; or oxetan-C1-6alkyl;
or R1 and Ra together with the atoms to which they are attached may form a three to six membered ring that may optionally include an additional heteroatom selected from O, N and S, and which is substituted with oxo, halo or C1-6alkyl;
R2 is: halo; C1-6alkoxy; cyano; C1-6alkynyl; C1-6alkenyl; halo-C1-6alkyl; halo-C1-6alkoxy; C3-6cycloalkyl wherein the C3-6cycloalkyl portion is optionally substituted with C1-6alkyl; C3-6cycloalkyl-C1-6alkyl wherein the C3-6cycloalkyl portion is optionally substituted with C1-6alkyl; tetrahydrofuranyl; tetrahydrofuranyl-C1-6alkyl; acetyl; oxetanyl; or oxetan-C1-6alkyl;
one of R3 and R4 is: halo; C1-6alkyl; C1-6alkoxy; C3-6cycloalkyloxy; halo-C1-6alkyl; or halo-C1-6alkoxy, and the other is hydrogen;
R5 is; oxo; C1-6alkyl; C3-6cycloalkyl; C3-6cycloalkyl-C1-6alkyl; or —C(O)—NRbRc wherein Rb and Rc each independently is hydrogen or —C1-6alkyl, or Rb and Rc together with the atoms to which they are attached may form a heterocyclyl group that optionally includes an additional heteroatom selected from O, N and S and which is optionally substituted one or more times with R6; and
each R6 is independently: C1-6alkyl; C3-6cycloalkyl; C3-6cycloalkyl-C1-6alkyl; halo; halo-C1-6alkyl; hydroxy-C1-6alkyl; C1-6alkoxy-C1-6alkyl; heterocyclyl; oxo; or —C(O)—NRbRc.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is —NH— or —O—.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is C1-6alkyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R2 is: halo; halo-C1-6alkyl; or cyano.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2 is chloro, trifluoromethyl or cyano.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R2 is trifluoromethyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R3 is halo or C1-6alkoxy.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R3 is halo or methoxy.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R4 is halo or C1-6alkoxy.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R4 is halo or methoxy.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R5 is: oxo; C1-6alkyl; or —C(O)—NRbRc.

### Claim 12 (depends on 1)

The compound of claim 1, wherein each R6 is independently: C1-6alkyl. hydroxy-C1-6alkyl. C1-6alkoxy-C1-6alkyl. heterocyclyl. oxo. or —C(O)—NRbRc.

### Claim 13 (depends on 1)

The compound of claim 1, wherein said compound is of formula IIa or IIb:
wherein:
m is: 0; 1 or 2;
Z is; —C(R7)2—; —NR8— or —O—; or Z is absent;
each R7 is independently: hydrogen; or C1-6alkyl; and
each R8 is independently: hydrogen; C1-6alkyl; C3-6cycloalkyl; C3-6cycloalkyl-C1-6alkyl; halo; halo-C1-6alkyl; hydroxy-C1-6alkyl; C1-6alkoxy-C1-6alkyl; heterocyclyl; or —C(O)—NRbRc.

### Claim 14 (depends on 1)

The compound of claim 1, wherein m is 0 or 1.

### Claim 15 (depends on 1)

The compound of claim 1, wherein Z is —C(R7)2—.

### Claim 16 (depends on 1)

The compound of claim 1, wherein Z is —NR8—.

### Claim 17 (depends on 1)

The compound of claim 1, wherein Z is —O—.

### Claim 18 (depends on 1)

The compound of claim 1, wherein Z is absent.

### Claim 19 (depends on 1)

A composition comprising:
(a) a pharmaceutically acceptable carrier; and
(b) a compound of claim 1.

### Claim 20 (depends on 1)

A method for treating Parkinson's disease, said method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
